Figure 3.

The clinical course of all patients treated with ATZ + BV, who were divided into mALBI grade 1 plus 2a (n = 15) and 2b plus 3 groups (n = 13). Abbreviations: AE—adverse event; CR—complete response; PR—partial response; SD—stable disease; PD—progressive disease; ATZ—atezolizumab; BV—bevacizumab.